ATA-3431

N/A

Report date: 2024/04/18 11:25:06

Base Information

Drug NameATA-3431

Drug Alias NameAllogeneic CD19/CD20 Bispecific CAR EBV T-cells therapy(Atara Biotherapeutics)ATA-3431

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators +[4]

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A